Mereo BioPharma Group plc
http://mereobiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mereo BioPharma Group plc
Ultragenyx Data De-Risk Phase III Trial Of Setrusumab
The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sanofi Ramps Up In Rare Diseases With Inhibrx Buy
The French major is paying up to $2.2bn to get access to Inhibrx’s alpha-1 antitrypsin deficiency candidate and to take a stake in the rest of the California-based biotech’s portfolio.
Will Anti-TIGITs Prove Their Value in 2023?
The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Mereo BioPharma Group Ltd.
- Mereo BioPharma Group plc (MPH:LN)
- OncoMed Pharmaceuticals, Inc. (OMED)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice